TY - JOUR AB - Breast cancer is the leading cause of cancer death in women worldwide. Insensitivity of tumor cells to drug therapies is an essential reason arousing such high mortality. Epithelial-mesenchymal transition (EMT) is defined by the loss of epithelial characteristics and the acquisition of a mesenchymal phenotype. It is well known that EMT plays an important role in breast cancer progression. Recently, mounting evidence has demonstrated involvement of EMT in antagonizing chemotherapy in breast cancer. Here, we discuss the biological significance and clinical implications of these findings, with an emphasis on novel approaches that effectively target EMT to increase the efficacy of anticancer therapies. AD - Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China AU - Huang,Jing AU - Li,Hongzhong AU - Ren,Guosheng DA - 2015/09/01 DO - 10.3892/ijo.2015.3084 EP - 848 IS - 3 JO - Int J Oncol KW - breast cancer epithelial-mesenchymal transition drug resistance cancer stem cells microRNA PY - 2015 SN - 1019-6439 1791-2423 SP - 840 ST - Epithelial-mesenchymal transition and drug resistance in breast cancer (Review) T2 - International Journal of Oncology TI - Epithelial-mesenchymal transition and drug resistance in breast cancer (Review) UR - https://doi.org/10.3892/ijo.2015.3084 VL - 47 ER -